If this broker is right, Sirtex Medical Limited shares could be a BARGAIN

Credit: Sirtex Medical

For Sirtex Medical Limited (ASX: SRX) shareholders, it’s been a tumultuous few months.

Source: Google Finance

Source: Google Finance

One look at the yearly chart above tells you it’s been a rocky ride for investors.

But while sharp rises and falls in share price are a regular feature in the biotechnology industry, the same cannot be said when the company is a profitable $1.6 billion leader in its own right.

The most recent share price fall, which took place last week, appears to have been a kneejerk reaction to slower-than-expected growth.

Yet, as my colleague Mike King showed yesterday, the company — although volatile — is still expecting to report sales growth of some 16%.

If this broker is right, Sirtex Medical Limited shares are a BARGAIN

According to Dow Jones Newswires, several major brokers updated their price targets on Sirtex Medical shares over the past week. Macquarie analysts cut their estimate of Sirtex’s fair value from $40 to $38, UBS has its target above $40, and Morgan Stanley set its target at $36.74.

If these brokers are right about Sirtex’s value, at its current price of $28.69, it could be in bargain territory.

Foolish takeaway

Of course, you should always take analysts’ price targets with a pinch of salt because using their estimates are no substitute for doing your own research. However, given the difference between consensus estimates and Sirtex Medical’s current share price, it may certainly be worthy of further consideration!

If you like Sirtex Medical, you'll love the stock The Motley Fool's expert analysts hand-picked as their best dividend share idea for 2016.

Indeed, our resident dividend experts named their Top Dividend Share for 2016, and not only are the shares dirt cheap, the company is growing and trading on a 5.6% fully franked dividend yield. Simply click here to gain access to this comprehensive FREE investment report, including the name of this fast growing ASX dividend share. No credit card required!

Motley Fool Contributor Owen Raszkiewicz does not have a financial interest in any company mentioned in this article. Owen welcomes -- and encourages -- your feedback on Google+, LinkedIn or you can follow him on Twitter @ASXinvest.

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.